Stock PMGM PRIVETERRA ACQUISITION CORP. II
Add to a list
To use this feature you must be a member
Log inSign up

News Priveterra Acquisition Corp. II

Equities

PMGM

US8765451047

Market Closed - Nasdaq
Other stock markets
 01:30:00 10/05/2024 am IST 		5-day change 1st Jan Change
11.05 USD -0.36% Intraday chart for Priveterra Acquisition Corp. II -.--% +0.55%
09/05 Priveterra Acquisition Corp. II(NasdaqCM:PMGM) dropped from NASDAQ Composite Index CI
2023 Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
AEON Biopharma Reports First Quarter 2024 Financial Results
AQ
AEON Biopharma Provides Update on Development Pipeline
AQ
Priveterra Acquisition Corp. II(NasdaqCM:PMGM) dropped from NASDAQ Composite Index
CI
Priveterra Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
BU
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
AQ
AEON Biopharma Announces Redemption of Public Warrants - March 29, 2024
AQ
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
AQ
AEON Biopharma Announces Redemption of Public Warrants
AQ
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
AQ
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
AQ
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
AQ
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
AQ
Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
AEON Biopharma Reports Third Quarter 2023 Financial Results
AQ
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
AQ
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
AQ
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
AQ
Priveterra Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Tastemaker Acquisition Corp. has Changed its Name to Priveterra Acquisition Corp. II
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PMGM Stock
  4. News Priveterra Acquisition Corp. II